Clearmind Medicine (Clearmind Medicine) Total Liabilities : $5.06 Mil (As of Jan. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Clearmind Medicine Total Liabilities?

Clearmind Medicine's Total Liabilities for the quarter that ended in Jan. 2024 was $5.06 Mil.

Clearmind Medicine's quarterly Total Liabilities increased from Jul. 2023 ($1.25 Mil) to Oct. 2023 ($3.59 Mil) and increased from Oct. 2023 ($3.59 Mil) to Jan. 2024 ($5.06 Mil).

Clearmind Medicine's annual Total Liabilities increased from Oct. 2021 ($0.29 Mil) to Oct. 2022 ($1.42 Mil) and increased from Oct. 2022 ($1.42 Mil) to Oct. 2023 ($3.59 Mil).

Clearmind Medicine Total Liabilities Historical Data

The historical data trend for Clearmind Medicine's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearmind Medicine Total Liabilities Chart

Clearmind Medicine Annual Data

Trend

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Total Liabilities

Get a 7-Day Free Trial

0.03

0.01

0.29

1.42

3.59

Clearmind Medicine Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Total Liabilities	Get a 7-Day Free Trial															0.80	1.94	1.25	3.59	5.06

Clearmind Medicine Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Clearmind Medicine's Total Liabilities for the fiscal year that ended in Oct. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3.594	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	3.59

Total Liabilities	=	Total Assets (A: Oct. 2023 )	-	Total Equity (A: Oct. 2023 )
	=	4.305	-	0.711
	=	3.59

Clearmind Medicine's Total Liabilities for the quarter that ended in Jan. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5.026	+	(0.031	+	-0.00099999999999975
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	5.06

Total Liabilities	=	Total Assets (Q: Jan. 2024 )	-	Total Equity (Q: Jan. 2024 )
	=	10.098	-	5.041
	=	5.06

Clearmind Medicine Total Liabilities Related Terms

Thank you for viewing the detailed overview of Clearmind Medicine's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Clearmind Medicine (Clearmind Medicine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearmind Medicine Inc (NAS:CMND) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

CWY0:Germany CWY0:Germany CMND:Canada

Address

101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H 1A5

Website

https://www.clearmindmedicine.com

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.